Deans' stroke musings

Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:http://oc1dean.blogspot.com/2010/11/my-background-story_8.html

Thursday, March 16, 2017

Oxford University to launch study on medical benefits of marijuana

Hopefully some stroke survivor has contacts there and can get stroke rehab on the study list.

My 13 reasons for marijuana use post-stroke.  

But don't listen to me, I have absolutely no medical training.


http://www.telegraph.co.uk/news/2017/03/16/oxford-university-launch-medical-marijuana-research-programme/
 


Researchers at Oxford University are to undertake a £10 million study on the medical benefits of marijuana in treating pain, cancer and inflammatory diseases.

It follows calls from some MPs for a law to allow medical use of cannabis, with polls suggesting  58 per cent of people would back such a move.
In recent years, studies have increasingly supported the medical value of cannabis in treating such conditions as multiple sclerosis, epilepsy and arthritis, and for dealing with nerve pain.
 


 
The study, entitled the Cannabis Research Plan, is to be a partnership between Oxford University and venture capital company Kingsley Capital Partners, who are investing £10 million to create a global centre of excellence in cannabinoid research.
Prof Ahmed Ahmed of Oxford's Nuffield Department of Obstetrics and Gynaecology, said existing studies were beginning to produce exciting findings which could result in new treatments. “This field holds great promise for developing novel therapeutic opportunities for cancer patients,” he said.
The study has received celebrity backing from actor Sir Patrick Stewart, who uses marijuana to treat the symptoms of his ortho-arthritis. He told The Daily Telegraph: “Two years ago, in Los Angeles I was examined by a doctor and given a note which gave me legal permission to purchase, from a registered outlet, cannabis-based products, which I was advised might help the ortho-arthritis in both my hands.”



Regular use of an ointment and chewy bar had allowed him to sleep at night, while spraying his hands during the day had brought back mobility, he said, enabling him to make fists.
“As a result of this experience, I enthusiastically support the Oxford University Cannabis Research Plan,” he said.
The star of the X-Men and Star Trek films hopes the research will help him and millions of others. “This is an important step forward for Britain in a field of research that has, for too long, been held back by prejudice, fear and ignorance,” he said.
Currently neither the Conservatives nor Labour officially support legalising cannabis for medical use. Both the Green Party and the Liberal Democrats have called for legalising its medical use for some time.
Sativex, a prescription-only drug used by multiple sclerosis patients, is the only licensed cannabis-based product in the country and is given to help ease muscle spasms. However, it is non-psychoactive and does not cause a high.
To date, NHS bodies have rejected its use, saying it is too costly to justify.

No comments:

Post a Comment